3D Systems Corporation (NYSE: DDD) saw its stock soar 5.19% in the pre-market trading session on Wednesday, driven by positive news surrounding its subsidiary, Systemic Bio.
Systemic Bio, a wholly-owned company of 3D Systems focused on accelerating drug discovery and development, has been named the winner of the prestigious SLAS 2025 Innovation Award. This award recognizes groundbreaking technological advancements poised to drive innovation in laboratory science and automation.
The award highlights Systemic Bio's proprietary h-VIOS™ platform, designed to accelerate drug discovery and development using bioprinted human tissues. The platform enables early identification of safety concerns, capturing risks that historically have only been discovered during clinical trials, even after non-human primate studies failed to flag such issues.